Modifiable and non-modifiable factors related to HPV infection and cervical abnormalities in women at high risk: a cross-sectional analysis from the Valhidate Study by G. Orlando et al.
Central
Bringing Excellence in Open Access

 Annals of Virology and Research
Cite this article: Orlando G, Tanzi E, Rizzardini G, Chatenoud L, Zanchetta N, et al. (2016) Modifiable and Non-Modifiable Factors Related to HPV Infection 
and Cervical Abnormalities in Women at High Risk: A Cross-Sectional Analysis from the VALHIDATE Study. Ann Virol Res 2(2): 1013.
*Corresponding author
Elisabetta Tanzi, Department of Biomedical Sciences for 
Health, University of Milan, via Carlo Pascal 36, 20133 
- Milan, Italy, Tel: 39-0250315139; Fax: 39-0250315120; 
Email: 
Submitted: 07 June 2016
Accepted: 30 June 2016
Published: 01 July 2016
Copyright
© 2016 Tanzi et al.
  OPEN ACCESS  
Keywords
•	HPV
•	HIV infected women
•	Migrant women
•	Pap screening
•	HPV testing
Research Article
Modifiable and Non-Modifiable 
Factors Related to HPV Infection and 
Cervical Abnormalities in Women 
at High Risk: A Cross-Sectional 
Analysis from the VALHIDATE Study
Orlando G1, Tanzi E2*, Rizzardini G1, Chatenoud L3, Zanchetta N4, 
Esposito S5, Tisi G6, Fasolo M1, Bosari S7, Boero V8, Matteelli A9, Bianchi 
S2, Frati ER2, Casolati E10, Fadelli S11, Lunghi G12, Antonacci C13†, 
Arcidiacono I14, Gargiulo F15, Marucci R16, Bertazzoli E17, Degiuli A18, 
Zuccotti G19, Galli C20, Gramegna M21, and VALHIDATE Study Group22
1Department of Infectious Diseases 1st, L Sacco University Hospital, Italy 
2Department of Biomedical Sciences for Health, University of Milan, Italy
3Department of Epidemiology, IRCCS Istituto di Ricerche Farmacologiche “Mario Negri,” Italy 
4Clinical Microbiology, Virology and Bio emergency, L. Sacco Teaching Hospital, Italy 
5Pediatric Highly Intensive Care Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore, Italy
6Department of Obstetrics and Gynecology, Spedali Civili di Brescia,Brescia, Italy
7Division of Pathology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Italy
8Department of Obstetrics and Gynecology, IRCSS Fondazione Cà Granda, Ospedale Maggiore 
Policlinico, Italy
9Department of Infectious and Tropical Diseases, University of Brescia, Italy
10Department of Obstetrics & Gynecology, L Sacco University Hospital, Italy 
11Health Centre “Opera San Francesco per i poveri Onlus”, Italy 
12Virology Unit, IRCCS Fondazione Ca’ Granda Policlinico,Milan, Italy
13Pathology Unit, L Sacco University Hospital, Italy 
14Department of Infectious Diseases, Lodi Hospital, Italy
15Laboratory of Microbiology, Spedali Civili General Hospital, Italy
16Pathology Unit, Spedali Civili General Hospital, Italy
17Department of Obstetrics and Gynaecology, Lodi Hospital, Italy
18Blood Transfusion Center, Lodi Hospital, Italy
19Department of Pediatrics, University of Milan, Italy 
20Department of Pathology, Lodi Hospital, Italy
21DG Salute, UO Governo della prevenzione e tutela sanitaria, Regione Lombardia, Italy
22VALHIDATE Study Group The eVALuation and monitoring of HPV Infections and relATEd 
cervical diseases in high-risk women (VALHIDATE) study group 
†Deceased
Abstract
Migrant women, and women infected with HIV, are at enhanced risk of cervical HPV infection and HPV-related cancers. We investigated factors that 
can reduce these risks through public health preventive and screening interventions. We studied the prevalence and risk factors for cervical HPV infection/
lesions in women with HIV-infection (HIW), in migrant women (RMW) and in a control group of resident women (SPW) who were enrolled in the study for the 
eVALuation and monitoring of HPV Infections and relATEd cervical diseases in high-risk women (VALHIDATE). Among 3093 evaluable women, age-standardized 
HPV prevalence was 36.3% (95%CI: 28.1–44.4) in HIW, 21.6% (95%CI: 15.7–27.5) in RMW, and 14.3% (95%CI: 12.5–16.1) in SPW. Adjusted prevalence 
of HPV infection was 2.07 times higher among HIW (95%CI: 1.75–2.45), and 1.45 times higher among RMW (95%CI: 1.17–1.80) than in SPW. Prevalence-
ratios of SIL and HG-SIL were 2.67 (95%CI: 2.06–3.45) and 2.82 (95%CI: 1.28–6.20), respectively, in HIW compared to controls. A multivariate log-
binomial regression model showed modifiable risk factors associated with HPV infection/lesion to have different patterns among groups. Specific public-health 
intervention, including health and sexual-health education, safe-sex procedures, and improvements to screening programmes, could favorably affect these 
highly vulnerable women.
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 ABBREVIATIONS
HIV: Human Immunodeficiency Virus; HPV: Human 
Papillomavirus; HIW: Women with HIV infection; RMW: Recent 
Migrant Women; SPW: Women who attended Spontaneous Pap-
screening Programs; VALHIDATE: eVALuation and Monitoring 
of HPV Infections and relATEd Cervical Diseases in High-
Risk Women; PCR: Polymerase Chain Reaction; STI: Sexually 
Transmitted Infection; HR-HPVs: High-Risk HPV; HG-SIL: High 
Grade Intraepithelial Lesions; eCRF: Electronic Case Report 
Form; ASC-US: Atypical Squamous Cells of Undetermined 
Significance; ASC-H: Atypical Squamous Cells that cannot exclude 
High-Grade SIL; LG/LSIL: Low Grade SIL; HSIL: High-Grade SIL; 
CA: Carcinoma; UNS: Unsatisfactory Specimens; CIN 1: Cervical 
Intraepithelial Neoplasia Grade 1; CIN 2: Cervical Intraepithelial 
Neoplasia Grade 2; PRs: Prevalence Ratios; PRadj,: Prevalence 
Ratios Adjusted; PR
crude
: Crude Prevalence Ratios; Cis: Confidence 
Intervals; cART: Combined Antiretroviral Treatment
INTRODUCTION
Infection with human papillomavirus (HPV) is a very common 
sexually transmitted infection (STI); the life-time risk of cervical 
HPV infection in women is estimated to be 80% [1]. Several 
co-factors beyond sexual exposure, such as age at first sexual 
intercourse, host susceptibility, other STIs, smoking, use of oral 
contraceptives and parity have also been associated to increased 
risk of infection and/or disease progression [2,3]. Although 
up to 90% of these infections clear within 2 years, persistent 
infection from a high-risk HPV genotype (HR-HPVs) can evolve 
to cancer. Although cervical cancer screening programs have 
led to a substantial decrease in its incidence, cervical cancer 
remains the third most common female cancer worldwide with 
the highest burden in developing countries, where more than 
80% of all the cervical cancer cases are detected [3,4]. The higher 
burden in resource limited settings primarily reflects lack of 
access to screening programs, which also contributes to the high 
prevalence of HPV infections and cancers in women migrating 
to industrialized world, who face language and social-economic 
barriers for healthcare access [5-13]. Host genetic factors [14] 
and impaired cell-mediated immunity, as with HIV-infected 
patients, are also associated with more persistent HPV infection 
and, thus, to increased risk of progression to cancer [15-19]. If 
the main cause of increased risk of progression to high grade 
intraepithelial lesions (HG-SIL) in HIV-infected patients is their 
inability to control replication and expression of HPV because 
of compromised immunity, the more widespread infection 
incidence seen in this population is probably also related to 
exposure to sexually transmitted infections and not entirely to 
impaired immunity. 
Epidemiological studies on cervical HPV prevalence in 
migrant women and in HIV-infected women showed wide 
variation in setting, age, cytology, and tests used, with prevalence 
ranging from 38–80%, but generally higher than those found 
in the control immune-competent population [5,7,12,20,21]. 
Disparities in distribution of HPV infection and HPV-related 
cervical diseases in highly vulnerable groups reflect the health 
system’s ability to reach all the target population, and underscore 
the need of specifically addressed public health interventions. 
Nowadays, prevention of HPV related diseases relies on HPV 
vaccine, regular screening and follow up, and sexual health 
education. This study aimed to provide an overview on factors 
associated with HPV infection and disease in two high-risk groups 
of women. We compared HIV+ women and migrant women in 
their first year of migration who had no health insurance, with 
a control group of resident women enrolled, between Nov 2010 
and Dec 2013, in the Lombardy Region epidemiological study for 
the eVALuation and monitoring of HPV infections and relATEd 
cervical diseases in high-risk women (VALHIDATE). This is an 
ongoing longitudinal prospective cohort study that focuses on 
clinical, virological and epidemiological characteristics of HPV 
infection and related cervical diseases in women at high risk for 
cervical cancer [22].
MATERIALS AND METHODS
Study Population 
The present study is the cross sectional report of the 
baseline evaluation of female population recruited in the 
VALHIDATE study [22] according to the protocol approved by 
the Ethical Committees of the participating centers. Enrollment 
was conducted inviting all women consecutively visiting seven 
clinical centers in four general hospitals (4 gynecology units 
and 3 infectious diseases units) and one faith-based outpatient 
department for migrants lacking health insurance. Each clinical 
centre provides a good experience in the implementation of 
population-based screening programs for cervical cancer which 
include a three-year recall of all women aged 25-64 years, in 
accordance with national Italian guidelines [23]. Migrant women 
who had arrived in Italy within 1 year (recent migrant women, 
RMW) and HIV-infected women (HIW) were considered as two 
distinct study groups of women at high risk for HPV infection and 
were compared with a control group of resident women aged 
18–65 years who attended spontaneous Pap-screening programs 
(SPW). Exclusion criteria were history of cervical cancer or 
surgically treated high-grade precancerous lesions, and refusal 
to sign the informed consent. Moreover, women in the SPW and 
RMW groups had not declared HIV status.
The enrollment was lower than expected by the protocol 
for all groups, reaching 77% of expected for HIW, 70% for SPW 
and 42% for RMW. The enrollment of young women less than 
26 years of age was 38% of expected (508 women). Therefore, 
this group was analyzed together with SPW group. No protocol 
violation was recorded for RMW and HIW groups.
Baseline evaluation
Baseline evaluations of the women were based on medical 
assessment by a gynecologist, and by an infectious disease 
specialist for the HIW patients; demographic, socioeconomic, 
behavioral data and medical history were collected and recorded 
on a specially designed electronic case report form (eCRF) 
from each participating centre. In the first screening round, all 
consenting women received both HPV testing and cytology. 
Cervical specimens were collected using a brush (Cytobrush 
Plus® Medscand Medical AB, Sweden) to perform a conventional 
Pap smear evaluated according to the 2001 Bethesda System 
terminology by expert cytopathologists of the participating 
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centers. Samples were classified as negative for cellular 
abnormalities (NEG), atypical squamous cells of undetermined 
significance (ASC-US), atypical squamous cells that cannot 
exclude high-grade SIL (ASC-H), low grade SIL (LSIL), high-grade 
SIL (HSIL), or carcinoma (CA). Unsatisfactory (UNS) specimens 
were excluded from the analysis. Colposcopy was performed in 
women with findings of ASC-US or worse and colposcopic driven 
biopsies were performed when indicated. Women with cervical 
intraepithelial neoplasia (CIN) grade 2 or more severe histological 
findings were referred for treatment. In cases of discordant 
cytology and histology, the more severe result was retained for 
analysis. Cyto/histological findings were then classified as low-
grade SIL (LG-SIL) encompassing ASC-US, LSIL, CIN1, and high-
grade SIL (HG-SIL) encompassing ASC-H, HSIL, CIN2 or worse.
The same cervical brush used for cytology was immersed 
and rinsed in 20 ml of PreservCyt® solution (ThinPrep Pap Test, 
Hologic Italia Srl, Italy), and stored at room temperature until 
HPV testing performed by the reference virology laboratory. Ten 
milliliters of each PreservCyt® solution containing cervical cells 
were centrifuged at 3800 ×g for 15 min at room temperature, 
then re-suspended in 1 mL of phosphate buffered saline (PBS), 
transferred into a new 1.5 mL collection test tube and stored at 
−20°C until nucleic acids extraction by NucliSENS® EasyMAG™ 
(bioMérieux, Lyon, France) commercial kit. The concentration 
and purity of the extracted DNA were evaluated using a 
spectrophotometer (Thermo Scientific NanoDrop 2000c; Thermo 
Fisher Scientific, Inc., Wilmington, DE). HPV DNA was detected 
by PCR amplification of a 450-bp segment of ORF L1 using the 
degenerate primer pair ELSI-f (5′-gCNCARggHCATAAYAATgg-3′) 
and ELSI-r (5′-CgNCCHAADggAAAYTgATC-3′) [24]. HPV DNA+ 
samples were genotyped by the INNO-LiPA™HPV Genotyping 
Extra (Fujirebio Italia, Roma, Italy) in microbiology laboratories 
of participating centres. Oncogenic risk of HPV types was 
assessed by the 2011 IARC classification [25]; genotypes 
classified as “carcinogenic”, “probably carcinogenic” or “possibly 
carcinogenic” to humans, all included in the High-Risk clade, 
were considered High-Risk HPV (HR-HPV) in these analyses.
Statistical analysis
Demographic and behavioral characteristics (age, 
geographical origin, marital status, level of education, smoking 
habits), reproductive and sexual health data (age at first sexual 
intercourse, parity, number of pregnancies and deliveries, 
spontaneous abortion, use of contraceptives and condoms, use 
of estroprogestinic drugs, menopause, number of lifetime and 
recent sexual partners, adherence to Pap screening programs, 
result of the Pap Test, history of sexually transmitted infections) 
and clinical data (history of diseases grouped by the major 
diagnostic categories scheme) were included in the analysis for 
the association with the prevalence of HPV infection. Differences 
in distribution of these factors between the control group and 
the RMW and HIW groups were compared using Pearson’s chi-
square test or Fisher’s exact test, as appropriate. Crude and 
age-standardized prevalence of HPV infection (applying direct 
method and using world population), were calculated with the 
corresponding 95% confidence intervals (95% CIs) for each study 
group. Prevalence of HPV was also calculated in strata of each 
factor considered in the analysis. To determine which factors were 
associated with HPV prevalence, prevalence ratios (PRs) for HPV 
infection, and corresponding 95% CIs, were calculated for each 
factor, using log-binomial regression in the three study groups. 
Multivariable models (PRadj) were used to control for potential 
confounding by factors that were significantly associated with 
HPV prevalence in the crude analysis, and for group-specific 
factors. When appropriate, Χ2 test for trend was also assessed. 
Adjustments are specified in table footnotes. Statistical analyses 
used SAS software, version 9.2 (SAS Institute Inc., Cary, NC). 
A similar analysis was performed for prevalence of cyto/
histological abnormalities, which were defined as the more 
severe finding of the Pap test or the cervical biopsy results. 
Crude prevalence was estimated for each study group, in strata 
of each factor considered in the analysis, and for HG-SIL only. 
Prevalence ratios for cyto/histological abnormality of any grade 
(and corresponding 95% CIs), were calculated for each study 
group using multivariable-models including study centre, age 
and number of lifetime sexual partners as covariates, when 
appropriate.
RESULTS 
Among 3185 women aged 18–65 years who gave their 
written informed consent, 3093 women were included in the 
analysis after the exclusion of 92 women (3%) for whom HPV 
or Pap test results were missing or inadequate (75 from the 
SPW group, 14 from the HIW group, 3 from the RMW group). 
Subjects included 1910 controls (SPW), 766 HIV infected women 
(HIW), and 417 recently immigrated women (RMW) (Table 1). 
The average refusal rate was 15%, with 3 out of the 8 centers 
showing a refusal rate lower than 10% and only 1 centre with a 
higher value of about 30%. Of the women in the HIW group, 708 
(92.8%) were on combined antiretroviral treatment (cART), with 
mean CD4+ cells counts of 599.9 cells/µL (95% CI: 578.8-621.1) 
and 636 (83.9%) had suppressed HIV viral loads (<50 copies/
µL). The most represented geographical origins of women in the 
RMW group were Latin America (237/417, 56.8%), followed by 
Eastern Europe (116/417, 27.8%).
Women with HIV infection (HIW) 
The women included in the HIW group were significantly 
different from the SPW group for most of the factors considered 
(Table 1). They were older, with a median age of 43 years 
compared with 34 years for the SPW group, they were more 
frequently foreign born (19% vs 7%), less frequently unmarried 
(27% vs 52%), less educated (51% were educated to the high 
school or university level, compared with 86% of the SPW group) 
and they were less frequently never-smokers (34% vs 61%). 
Women in the HIW group were younger at the time of their 
first sexual intercourse, 39% had more than five lifetime sexual 
partners compared with 22% in the control group, but tended 
to have had fewer partners in the last 6 months (26% declared 
no partners in the last 6 months compared with 7% in the SPW 
group). Condoms were the preferred contraceptive method in 
the HIW group (52.5%), whereas estroprogestinic drugs were 
preferred in the SPW group (70%). Parity was higher among 
HIW patients (76.8% vs 45.8%), and a higher percentage were in 
menopause than the SPW group (19% vs 7%).
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Table 1: Distribution of selected socio-demographics characteristics, smoking and sexual habits, reproductive and gynecological history, in the three 
study groups: controls (SPW), HIV infected women (HIW), and recent migrant women (RMW).
SPW
N=1910
HIW
N=766
RMW
N=417
Statistica
(p-value)
HIW vs SPW
Statistica
(p-value)
RMWvs SPWN % N % N %
Age (years)
508 26.6% 33 4.3% 153 36.7%
18-25
<0.01 <0.01
26-35 525 27.5% 120 15.7% 143 34.3%
36-45 620 32.5% 333 43.5% 117 28.0%
>45 257 13.4% 280 36.5% 4 1.0%
Median / Mean
(95% CI)
34.0 / 34.3
(33.8-34.8)
43.0 / 42.0
(41.4-42.6)
29.0 / 30.1
(29.4-30.9)
<0.01 <0.01
Geographical origin
Italy 1768 92.6% 620 80.9% 0 0.0%
<0.01 <0.01
Africa 15 0.8% 83 10.8% 44 10.6%
Asia 6 0.3% 9 1.2% 20 4.8%
Europe 66 3.4% 25 3.3% 116b 27.8%
Latin America 55 2.9% 29 3.8% 237 56.8%
Marital status
988 51.7% 209 27.3% 180 43.2%
Unmarried
<0.01 <0.01
Married 681 35.7% 266 34.7% 159 38.1%
Cohabitant 103 5.4% 113 14.8% 35 8.4%
Other (divorced or widow) 138 7.2% 178 23.2% 43 10.3%
Educationc
Primary school 269 14.1% 375 49.0% 148 35.5%
<0.01 <0.01Secondary school 1047 54.8% 332 43.3% 205 49.2%
University degree 594 31.1% 58 7.6% 64 15.3%
Smoking habit
1173 61.4% 261 34.1% 345 82.7%
Never smoker
<0.01 <0.01Ex smoker 206 10.8% 153 20.0% 14 3.4%
Current smoker 531 27.8% 352 45.9% 58 13.9%
1-10 cig./day 377 71.0% 140 39.8% 40 69.0%
<0.01 NS
> 10 cig./day 154 29.0% 212 60.2% 18 31.0%
Age at first sexual 
intercoursec
≤16 476 24.9% 298 38.9% 111 26.6%
<0.01 NS17-18 713 37.3% 276 36.0% 141 33.8%
≥19 710 37.2% 181 23.6% 164 39.3%
Median / Mean
(95% CI)
18.0 / 18.5
(18.4-18.7)
17.0 / 17.4
(17.2-17.6)
18.0 / 18.4
(18.1-18.8)
<0.01 NS
SPW
N=1910
HIW
N=766
RMW
N=417
Statistica
(p-value)
HIW vs SPW
Statistica
(p-value)
RMWvs SPWN % N % N %
Number of lifetime
sexual partnersc
1 465 24.3% 69 9.0% 140 33.6%
<0.01 <0.012-5 1029 53.9% 389 50.8% 248 59.5%
>5 414 21.7% 302 39.4% 28 6.7%
Number of sexual partners in 
the last 6 monthsc
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SPW
N=1910
HIW
N=766
RMW
N=417
Statistica
(p-value)
HIW vs SPW
Statistica
(p-value)
RMWvs SPWN % N % N %
0 138 7.2% 198 25.8% 150 36.0%
<0.01 <0.011 1647 86.2% 543 70.9% 247 59.2%
≥2 119 6.2% 16 2.1% 16 3.8%
Use of any type of 
contraceptive methodsc
Never 197 10.3% 67 8.7% 91 21.8%
NS <0.01Only past use 747 39.1% 276 36.0% 176 42.2%
Current use 962 50.4% 418 54.6% 150 36.0%
Use of condomc
Never 764 40.0% 146 19.1% 242 58.0%
<0.01 <0.01Only past use 663 34.7% 208 27.2% 83 19.9%
Current use 468 24.5% 402 52.5% 68 16.3%
Use of IUDc
Never 1761 92.2% 688 89.8% 356 85.4%
<0.01 0.03Only past use 93 4.9% 64 8.4% 20 4.8%
Current use 39 2.0% 3 0.4% 17 4.1%
Use of other contraceptive 
methodsc,d
Never 1870 97.9% 738 96.3% 320 76.7%
NS <0.01Only past use 22 1.2% 13 1.7% 71 17.0%
Current use 0 0.0% 1 0.1% 2 0.5%
Use of Estro-progestinic 
drugs (EP)c
Never 573 30.0% 392 51.2% 255 61.2%
<0.01 <0.01
Only past use 851 44.6% 341 44.5% 99 23.7%
Only current use 197 10.3% 2 0.3% 20 4.8%
Past and current use 272 14.2% 18 2.4% 19 4.6%
Years of usec ≤5 135 49.6% 10 55.6% 14 73.7%
NS 0.03
>5 124 45.6% 8 44.4% 4 21.1%
SPW
N=1910
HIW
N=766
RMW
N=417
Statistica
(p-value)
HIW vs
SPW
Statistica
(p-value)
RMW vs
SPWN % N % N %
Number of childrenc
0 1144 59.9% 343 44.8% 165 39.6%
<0.01 <0.011 314 16.4% 248 32.4% 126 30.2%
≥2 450 23.6% 174 22.7% 126 30.2%
Number of pregnanciesc
0 1035 54.2% 178 23.2% 127 30.5%
<0.01 <0.01
1 298 15.6% 226 29.5% 108 25.9%
2 348 18.2% 190 24.8% 86 20.6%
≥3 226 11.8% 170 22.2% 96 23.0%
Spontaneous abortionc
No 1696 88.8% 643 83.9% 365 87.5%
<0.01 NS
Yes 212 11.1% 122 15.9% 52 12.5%
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SPW
N=1910
HIW
N=766
RMW
N=417
Statistica
(p-value)
HIW vs
SPW
Statistica
(p-value)
RMW vs
SPWN % N % N %
Menopausec
No 1753 91.8% 604 78.9% 401 96.2%
<0.01 0.01
Yes 140 7.3% 144 18.8% 16 3.8%
History of STIs and/or 
genital infectionsc
No 1281 67.1% 370 48.3% 328 78.7%
<0.01 <0.01
Yes 622 32.6% 388 50.7% 85 20.4%
History of STIs and/or 
genital infections by typesc
Genital warts 86 4.5% 139 18.2% 5 1.2% <0.01 <0.01
Mycosis 485 25.4% 187 24.4% 47 11.3% NS <0.01
Bacterial vaginosis 63 3.3% 96 12.5% 24 5.8% <0.01 0.02
HSV 39 2.0% 53 6.9% 1 0.2% <0.01 0.01
Trichomoniasis 23 1.2% 28 3.7% 0 0.0% <0.01 -
Chlamydia 26 1.4% 17 2.2% 1 0.2% NS NS
Syphilis 1 0.1% 23 3.0% 1 0.2% <0.01 NS
Gonorrhea 0 0.0% 6 0.8% 1 0.2% - -
LGV 1 0.1% 2 0.3% 1 0.2% NS NS
At least one STI, other than 
warts
536 28.1% 249 32.5% 80 19.2% <0.01 <0.01
SPW
N=1910
HIW
N=766
RMW
N=417
Statistica
(p-value)
HIW vs
SPW
Statistica
(p-value)
RMW vs
SPWN % N % N %
Previous PAP screening timingc
Regular timing (every 2-3 years) 1296 67.9% 569 74.3% 114 27.3%
<0.01 <0.01Irregular timing 299 15.7% 158 20.6% 87 20.9%
Never done 309 16.2% 33 4.3% 216 51.8%
Previous PAP screening resultc
Never done 309 16.2% 33 4.3% 216 51.8%
<0.01 <0.01Negative 1518 79.5% 614 80.2% 195 46.8%
Positive 57 3.0% 85 11.1% 4 0.9%
Unknown 24 1.3% 30 3.9% 2 0.5%
History of chronic or relevant diseasesc,e
No 1240 64.9% 389 50.8% 278 66.7%
<0.01 NS
Yes 668 35.0% 377 49.2% 139 33.3%
NS: Not significant.aChi-square test, Fisher exact Test or T test.
bAll women came from Eastern Europe.
cThe sum does not up to the total because of missing values.dOther contraceptive methods include: injections of hormones, ovules, tube tied, vaginal ring.eDiseases classified according to Major Diagnostic Categories (MDC – version 24).
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History of STIs was significantly higher for HIW, 51% of whom 
reported having had at least one condition compared with 33% 
in the SPW group, and genital warts were exceedingly higher in 
the HIW group (18%) than in the SPW (4.5%). Only 4% of the 
HIW group had never had a Pap smear previously compared with 
16% of the SPW group, and they had more frequent positive Pap 
screening results (11% vs 3%).
Recent migrant women (RMW) 
The RMW group also differed from controls for most of 
the factors considered. Women in this group were younger 
than controls, with a median age of 29 years. They were less 
educated, 65% were educated to the high school or university 
level compared with 86% in the control group and most of them 
were never-smokers (83% vs 61%). About 34% claimed only one 
partner in their lives and 36% claimed no partners in the last six 
months, compared with 24% and 7%, respectively, in the control 
group. A higher percentage of the RMW group claimed to use no 
contraceptive method than did the SPW group (22% vs 10%). 
Parity was higher in RMW (69.5% vs 45.8%). History of STIs was 
significantly lower for RMW only 20% of whom reported having 
had at least one condition. Finally, about 52% of them declared 
that they had never had a Pap smear previously, compared with 
16% of the control group. 
Prevalence of HPV infection and SIL 
A total of 572 women (18.5%; 95% CI: 17.13–19.86) had a 
positive HPV DNA test among the 3093 women analyzed: SPW: 
273; HIW: 215; RMW: 84. Age-standardized HPV prevalence 
was SPW: 14.3% (95% CI: 12.5–16.1); HIW: 36.3% (95% CI: 
28.1–44.4); RMW: 21.6% (95% CI: 15.7–27.5) (Figure 1a). Most 
infections were sustained by HR-HPV types in all groups. Among 
HPV-infected women, crude prevalence of infection from at 
least one HR-HPV type was SPW: 85.72%; HIW: 76.74%; RMW: 
85.60%. The adjusted prevalence ratio (PRadj) of HPV infection 
compared with controls was HIW: 2.07 (95% CI: 1.75–2.45); 
RMW: 1.45 (95% CI: 1.17–1.80) (Table 2).
Squamous intraepithelial lesions (SIL) were found in 
cytological and/or histological samples in 288 women (9.3%; 
95% CI: 8.29–10.34)—specifically, SPW: 128 (6.7%, 95% CI: 
5.6–7.8); HIW: 125 (16.3%, 95% CI: 13.7–18.9); RMW: 35 (8.4%, 
95% CI: 5.9–11.5) (Figure 1b). When type of cyto/histological 
abnormality was considered, HG-SIL was seen in 13 women in 
the SPW group (0.7%; 95% CI: 0.4–1.2), 17 in the HIW group 
(2.2%; 95% CI: 1.3–3.5), and 6 in the RMW group (1.4%; 95% CI: 
0.5–3.1) (Figure 1b).
The HIW had significantly higher prevalence of any grade 
SIL (PRadj: 2.67; 95% CI: 2.06–3.45) and HG-SIL (PRadj: 2.82; 
95% CI: 1.28–6.20) than did the controls. The RMW group had 
higher prevalence of any grade SIL than did the controls, (PRadj: 
1.26; 95% CI: 0.88–1.81) and HG-SIL (PRadj: 2.22; 95% CI: 0.83–
5.92) but the adjusted prevalence rate did not reach a statistical 
significance (Table 2). 
Effect of age on prevalence of HPV infection and SIL 
A significant decreasing trend in HPV prevalence by age was 
observed in the three study groups (Figure 2a, Table 3), and was 
most pronounced in the HIW group, with HPV prevalence of 
51.5% (95% CI: 33.5–69.2) in the 18–25 years old (y.o.) subgroup 
(considered as reference category), followed by 41.7% in 26–
35 y.o. women and 24% in both those 36–45 y.o. and >45 y.o., 
Figure 1a Prevalence of HPV Infection.  Crude and Age-standardized(world population)prevalence (P) of HPV infection and corresponding 95% 
confidence intervals (CI), in the control group (SPW), the HIV infected women group (HIVW), and recent migrant women group (RMW).
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Figure 1b Prevalence of SIL and HG-SIL. Crude prevalence (P)and corresponding 95% confidence intervals (CI) of any cyto/histological 
abnormality and high grade intraepithelial lesions in the control group (SPW), the HIV infected women group (HIVW), and the recent migrant 
women group (RMW).
Figure 2a Prevalence of HPV Infection. Prevalence and corresponding 95% confidence intervals (CI) of HPV infection by age groups, in the control 
group (SPW), the HIV infected women group (HIVW), and the recent migrant women group (RMW).
reflecting risk reductions of about 19% (PR
crude
: 0.81) and 53% 
(PR
crude
: 0.47) respectively (Table 3). 
The control group showed a similar trend, although HPV 
prevalence was always lower than in the HIW group (Figure 2a). 
Age-specific HPV prevalence decreased from 21.3% to 8.4 in 
18–25 y.o., 36-45 y.o. women (PR
crude
: 0.39, 95% CI: 0.29–0.54). 
The RMW group showed a less marked downward trend; age-
specific prevalence was always higher than controls, and ranged 
from 27.5% in 18–25 y.o. women to 12.8% in 36–45 y.o. women 
(PR
crude
: 0.47; 95% CI: 0.27–0.80). We had too few subjects older 
than 45 years in this study group to allow any comparison for this 
age group. The prevalence ratio of SIL (any grade) was reduced in 
SPW older than 25 years and stable for HIW and RMW. Correlation 
between age and HG-SIL were not investigated because of the low 
number of events observed in all study groups (Table 4). In the 
HIW group, the prevalence of SIL was significantly higher through 
all age groups compared with controls, with a prevalence of 24% 
(95% CI: 11.1–42.3) for women aged 18–25 years and 17% 
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Figure 2b Prevalence of HPV Infection. Prevalence and corresponding 95% confidence intervals (CI) of HPV infection by age groups, in the control 
group (SPW), the HIV infected women group (HIVW), and the recent migrant women group (RMW).
(95% CI: 12.9–22.1) for women aged 45 years or older (Table 4). 
Because of the low number of SIL observed in the RMW group (35 
out of 417 women), the result interpretation was not possible for 
this study group.
Other factors associated to HPV prevalence
We investigated the association between a wide range of 
factors and the prevalence of HPV infection for each study group 
(Table 3) and summarized the factors significantly associated to 
HPV prevalence also when major confounders were considered 
(Figure 3a). In the multivariate log-binomial regression model, 
the main factors significantly associated to HPV prevalence in 
at least one of the three study groups were age, marital status, 
smoking habits, number of lifetime sexual partners, use of any 
contraceptive method, use of condoms, number of pregnancies 
and deliveries, having had STI (mainly genital warts), and 
previous positive Pap screening results; however, the strength 
(and significance) of the associations differed among groups 
(Table 3). Figure 3a shows all the factors modifiable by specifically 
addressed health information campaigns and significantly 
associated with change in HPV prevalence for at least one of the 
groups studied in this analysis. 
Other factors associated to SIL 
The prevalence of any grade SIL and its corresponding 
estimated prevalence ratio, and the prevalence of HG-SIL, for 
all factors considered in the HPV analysis are shown in Table 
(4). Figure 3b summarizes factors associated significantly to 
prevalence of any grade SIL in the adjusted models (which 
considered only major potential confounders—study centre, 
age and number of partners, when appropriate—because of a 
low number of positive tests). The main factors significantly 
associated to SIL in at least one of the three study groups were 
age, marital status, smoking habits, number of lifetime sexual 
partners, condom use, history of genital warts, adherence to Pap 
screening programs and results of previous Pap screening (Table 
4). Figure (3b) shows modifiable factors significantly found to 
change prevalence in cervical abnormalities for at least one of 
the groups analyzed. 
DISCUSSION
We report the results of the cross-sectional part of the 
VALHIDATE study based on a co-testing evaluation (cytology 
and HPV testing plus genotyping), designed to be representative 
of women at high risk of HPV infection and related cervical 
diseases across a wide age range. Although this study is from a 
limited geographic area, it is the first population-based study on 
prevalence, age distribution, and risk factors for HPV infection 
and related cervical lesions in HIV-infected women (HIW) and 
recently migrant women (RMW) compared with a control group 
(SPW) of women resident in Lombardy (Italy). The crude, age-
standardized prevalence and adjusted prevalence ratio of HPV 
infection are significantly higher in the testing groups than in the 
control group of resident women; and the crude and adjusted 
prevalence ratios of cervical intraepithelial abnormalities (any 
grade and high-grade SIL) were higher in HIW than in the control 
group. Cervical cancer prevention strategies are evolving because 
of the introduction of preventive vaccines and the availability 
of HPV testing for primary screening in addition to the well-
established effectiveness of cytology screening introduced in the 
mid-50s. 
Randomized trials [26-28] have shown that HPV testing 
provides greater sensitivity than cytology for detection of CIN, 
and that the detection of high-risk HPV types could be a better 
predictor of increased risk [29,30]. However, as reflex cytology 
is needed to detect underlying cellular abnormalities in HPV+ 
women, HPV testing is recommended for those older than 30 
years when the prevalence of transient infections falls. In the 
ARTISTIC trial [31] infection prevalence from high risk HPV 
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Figure 3a Adjusted PR (95%CI) for modifiable factors significantly associated to HPV infection in at least one study group (i.e. controls: SPW, the 
HIV-positive women: HIVW and the recent migrant women: RMW). Diamonds correspond to significant PR.
Figure 3b Adjusted PR (95%CI) for modifiable factors significantly associated to cyto/histological abnormalities in at least one study group (i.e. 
controls: SPW, the HIV-positive women: HIVW and the recent migrant women: RMW). Diamonds correspond to significant PR.
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Table 2: Prevalence and prevalence ratios (PR) comparing the HIW and the RMW groups versus the SPW group, and corresponding 95% confidence 
intervals (CI), for HPV infection, and cyto/histological abnormalities (any grade and HG-SIL).
SPW
N=1910
HIW
N=766
RMW
N=417
N % N % N %
HPV positive test result 273 14.3% 215 28.1% 84 20.1%
Crude PRa (95% CI) 1c 1.96 (1.68-2.30) 1.41 (1.13-1.76)
Adjusted PRb (95% CI) 1c 2.07 (1.75-2.45) 1.45 (1.17-1.80)
Any grade SIL 128 6.7% 125 16.3% 35 8.4%
Crude PRa (95% CI) 1c 2.44 (1.93-3.07) 1.25 (0.88-1.79)
Adjusted PRd (95% CI) 1c 2.67 (2.06-3.45) 1.26 (0.88-1.81)
HG-SIL 13 0.7% 17 2.2% 6 1.4%
Crude PRa (95% CI) 1c 3.26 (1.59-6.68) 2.11 (0.81-5.53)
Adjusted PRd (95% CI) 1c 2.82 (1.28-6.20) 2.22 (0.83-5.92)aPrevalence ratio estimates from univariate log-binomial regression model.
bPrevalence ratio estimates from multivariate log-binomial regression model adjusted for age groups, smoking habit, and number of lifetime sexual 
partners.
cReference category.dPrevalence ratio estimates from multivariate log-binomial regression model adjusted for age groups and number of lifetime sexual partners.
Table 3: Number (N), prevalence (P), and prevalence ratios (PR) of HPV infection and corresponding 95% confidence intervals (CIs), according to 
selected socio-demographics characteristics, smoking and sexual habits, reproductive and gynecological history, in the control group (SPW), the HIV 
group (HIW), and the recent migrant group (RMW).
SPW (N=1910) HIW (N=766) RMW (N=417)
HPV 
infection 
N=273
N (P)
Crude
PRa
(95% CI)
Adjusted
PRb
(95% CI)
HPV 
infection 
N=215
N (P)
Crude
PRa
(95% CI)
Adjusted
PRc
(95% CI)
HPV 
infection 
N=84
N (P)
Crude
PRa
(95% CI)
Adjusted
PRd
(95% CI)
Age (years)
18-25 108 (21.3) 1e 1e 17 (51.5) 1e 1e 42 (27.5) 1e 1e
26-35 92 (17.5)
0.82
(0.64-1.06)
0.72
(0.56-0.93) 50 (41.7)
0.81
(0.55-1.20)
0.84
(0.60-1.17)
27 (18.9)
0.69
(0.45-1.05)
0.66
(0.43-1.02)
36-45 52 (8.4)
0.39
(0.29-0.54)
0.40
(0.29-0.55) 80 (24.0)
0.47
(0.32-0.68)
0.48
(0.34-0.67) 15 (12.8)
0.47
(0.27-
0.80)
0.46
(0.27-0.78)
>45 21 (8.2)
0.38
(0.25-0.60)
0.45
(0.29-0.69) 68 (24.3)
0.47
(0.32-0.70)
0.49
(0.35-0.70) 0 (0.0) - -
χ2trend (p-value) 43.42 (<0.001)
36.67 
(<0.001)
20.23 
(<0.001) 22.60 (<0.001)
8.63 
(0.003)
10.36 
(0.001)
Geographical 
origin
Italy 250 (14.1)
0.87
(0.59-1.29)
0.84
(0.59-1.21)
168 (27.1)
0.84
(0.64-1.10)
0.90
(0.67-1.19)
- - -
Africa 3 (20.0)
1.40
(0.51-3.89)
2.03
(0.77-5.40)
27 (32.5)
1.18
(0.85-1.65)
1.15
(0.81-1.61)
8 (18.2)
0.89
(0.46-1.72)
0.96
(0.50-1.83)
Asia 0 (0.0) - - 1 (11.1)
0.39
(0.06-2.50)
NA 1 (5.0)
0.24
(0.04-1.63)
NA
Europe 12 (18.2)
1.28
(0.76-2.17)
1.10
(0.68-1.79)
8 (32.0)
1.15
(0.64-2.05)
1.04
(0.59-1.82)
23 (19.8)
0.98
(0.64-1.50)
0.92
(0.60-1.41)
Latin America 8 (14.5)
1.02
(0.53-1.95)
1.28
(0.70-2.34)
11 (37.9)
1.37
(0.85-2.21)
1.27
(0.77-2.09)
52 (21.9)
1.23
(0.83-1.83)
1.20
(0.81-1.78)
Marital status
Unmarried 196 (19.8) 1e 1e 77 (36.8) 1e 1e 47 (26.1) 1e 1e
Married 35 (5.1)
0.26
(0.18-0.37)
0.44
(0.30-0.65) 54 (20.3)
0.55
(0.41-0.74)
0.65
(0.47-0.89) 21 (13.2)
0.51
(0.32-
0.81)
0.61
(0.37-1.00)
Cohabitant 17 (16.5)
0.83
 (0.53-1.31)
0.89
 (0.57-1.40)
36 (31.9)
0.86 
(0.63-1.19)
0.90
 (0.66-1.24)
8 (22.9)
0.88 
(0.45-1.69)
0.90 
(0.47-1.72)
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Table 3: Number (N), prevalence (P), and prevalence ratios (PR) of HPV infection and corresponding 95% confidence intervals (CIs), according to 
selected socio-demographics characteristics, smoking and sexual habits, reproductive and gynecological history, in the control group (SPW), the HIV 
group (HIW), and the recent migrant group (RMW).
SPW (N=1910) HIW (N=766) RMW (N=417)
HPV 
infection 
N=273
N (P)
Crude
PRa
(95% CI)
Adjusted
PRb
(95% CI)
HPV 
infection 
N=215
N (P)
Crude
PRa
(95% CI)
Adjusted
PRc
(95% CI)
HPV 
infection 
N=84
N (P)
Crude
PRa
(95% CI)
Adjusted
PRd
(95% CI)
Other (divorced or 
widow)
25 (18.1)
0.91
 (0.63-1.33)
1.31 
(0.86-1.98)
48 (27.0)
0.73 
(0.54-0.99)
0.88
(0.63-1.21)
8 (18.6)
0.71
 (0.36-
1.39)
0.83 
(0.41-1.67)
Education
Primary school 28 (10.4) 1e 1e 107 (28.5) 1e 1e 32 (21.6) 1e 1e
Secondary school 148 (14.1)
1.36 
(0.93-1.99)
1.07 
(0.74-1.55)
89 (26.8)
0.94
 (0.74-1.19)
0.92 
(0.73-1.16)
42 (20.5)
0.95
 (0.63-
1.43)
0.86
 (0.57-1.29)
University degree 97 (16.3)
1.57 
(1.06-2.33)
1.20 
(0.81-1.76)
18 (31.0)
1.09 
(0.72-1.65)
1.13 
(0.76-1.67)
10 (15.6)
0.72 
(0.38-1.38)
0.68
 (0.36-1.28)
χ2trend (p-value) 5.09 (0.024) 1.23 (0.268) 0.00 (0.967) 0.00 (0.960) 0.81 
(0.369)
1.56 (0.211)
SPW (N=1910) HIW (N=766) RMW (N=417)
HPV infection 
N=273
N (P)
Crude
PRa
(95% CI)
Adjusted
PRb
(95% CI)
HPV infection 
N=215
N (P)
Crude
PRa
(95% CI)
Adjusted
PRc
(95% CI)
HPV 
infection 
N=84
N (P)
Crude
PRa
(95% CI)
Adjusted
PRd
(95% CI)
Smoking habit
Never/ Ex 
smoker
170 (12.3) 1e 1e 99 (24.0) 1e 1e 73 (20.3) 1e 1e
Current smoker 103 (19.4)
1.57 
(1.26-1.97)
1.30 
(1.04-1.62) 116 (33.0)
1.38
 (1.10-1.73)
1.38
 (1.10-1.73) 11 (19.0)
0.93
 (0.53-1.65)
0.84
(0.47-1.51)
 1-10 cig/day 71 (18.8)
1.53
 (1.19-1.97)
1.18 
(0.92-1.52)
44 (31.4)
1.31 
(0.97-1.77)
1.39 
(1.04-1.88) 8 (20.0)
1.98 
(0.51-1.89)
0.87 
(0.45-1.68)
>10 cig/day 32 (20.8)
1.69 (1.20-
2.37)
1.56 (1.13-
2.16) 72 (34.0)
1.42 (1.10-
1.83)
1.37 (1.06-
1.76) 3 (16.7)
0.82 
(0.29-2.35)
0.78 
(0.27-2.24)
 χ2trend 
(p-value)
15.53 
(<0.001) 7.36 (0.007) 7.73 (0.005) 6.18 (0.013) 0.11 (0.745) 0.35 (0.556)
Age at first sexual 
intercourse
≤16 83 (17.4) 1e 1e 93 (31.2) 1e 1e 28 (25.2) 1e 1e
17-18 105 (14.7)
0.84
 (0.65-1.10)
1.07 
(0.83-1.39)
69 (25.0)
0.80
 (0.61-1.04)
0.92
 (0.71-1.20)
28 (19.9)
0.79
(0.50-1.25)
0.84
 (0.53-1.33)
≥19 84 (11.8)
0.68 
(0.51-0.90)
1.18 
(0.88-1.59)
47 (26.0)
0.83
 (0.62-1.12)
1.01 
(0.72-1.41)
28 (17.1)
0.68
 (0.43-1.08)
0.78 
(0.49-1.26)
χ2trend (p-value) 7.44 (0.006) 0.35 (0.554) 2.02 (0.155) 0.02 (0.885) 2.67 (0.102) 1.00 (0.317)
Number or lifetime sexual partners
1 19 (4.1) 1e 1e 11 (15.9) 1e 1e 23 (16.4) 1e 1e
2-5 154 (15.0)
3.66
 (2.30-5.82)
3.42
 (2.15-5.44) 106 (27.2)
1.71
 (0.97-3.01)
1.59
(0.91-2.78)
51 (20.6)
1.25
(0.80-1.96)
1.31
(0.84-2.05)
>5 100 (24.2)
5.91
 (3.69-9.48)
5.47
 (3.39-8.81) 95 (31.5)
1.97
 (1.12-3.48)
1.68
(0.96-2.97)
10 (35.7)
2.17 
(1.17-4.05)
2.25 
(1.23-4.14)
χ2trend (p-value) 70.16 (<0.001)
60.87 
(<0.001) 5.75 (0.017) 2.32 (0.128) 4.39 (0.036) 5.37 (0.021)
Number of sexual partners in the last 6 months
0 21 (15.2) 1e 1e 62 (31.3) 1e 1e 31 (20.7) 1e 1e
1 210 (12.8)
0.84
 (0.55-1.27)
0.76 
(0.51-1.13)
146 (26.9)
0.86 
(0.67-1.10)
0.82
 (0.65-1.05)
50 (20.2)
0.98
(0.66-1.46)
0.89
 (0.59-1.33)
≥2 42 (35.3)
2.32
(1.46-3.68)
1.11 
(0.70-1.76)
5 (31.3)
1.00 
(0.47-2.12)
0.82 
(0.35-1.92)
3 (18.8)
0.91
(0.31-2.64)
0.74 
(0.25-2.13)
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SPW (N=1910) HIW (N=766) RMW (N=417)
HPV infection 
N=273
N (P)
Crude
PRa
(95% CI)
Adjusted
PRb
(95% CI)
HPV infection 
N=215
N (P)
Crude
PRa
(95% CI)
Adjusted
PRc
(95% CI)
HPV 
infection 
N=84
N (P)
Crude
PRa
(95% CI)
Adjusted
PRd
(95% CI)
χ2trend (p-value) 22.73 (<0.001) 1.67 (0.196) 1.01 (0.316) 2.56 (0.110) 0.03 (0.867) 0.52 (0.470)
Use of any type of contraceptive methods
Never 18 (9.1) 1e 1e 26 (38.8) 1e 1e 19 (20.9) 1e 1e
Only past use 90 (12.1)
1.32 
(0.82-2.13)
1.11
 (0.69-1.77)
69 (25.0)
0.64
 (0.45-0.93)
0.68 
(0.48-0.96) 34 (19.3)
0.93 
(0.56-1.53)
0.79 
(0.47-1.32)
Current use 165 (17.2)
1.88 
(1.18-2.98)
1.19
 (0.75-1.89)
116 (27.8)
0.72 
(0.51-1.00)
0.69 
(0.51-0.95) 31 (20.7)
0.99 
(0.60-1.65)
0.80 
(0.48-1.34)
SPW (N=1910) HIW (N=766) RMW (N=417)
HPV 
infection 
N=273
N (P)
Crude
PRa
(95% CI)
Adjusted
PRb
(95% CI)
HPV infection 
N=215
N (P)
Crude
PRa
(95% CI)
Adjusted
PRc
(95% CI)
HPV 
infection 
N=84
N (P)
Crude
PRa (95% CI) AdjustedPRd (95% CI)
Use of condom 
Never 104 (13.6) 1e 1e 47 (32.2) 1e 1e 50 (20.7) 1e 1e
Only past use 90 (13.6)
1.00 
(0.77-1.30)
0.77 
(0.60-1.00) 51 (24.5)
0.76
 (0.54-1.06)
0.75 
(0.54-1.04)
17 (20.5)
0.99
 (0.61-1.62)
0.83 
(0.51-1.36)
Current use 77 (16.5)
1.21
 (0.92-1.59)
0.84 
(0.64-1.10)
112 (27.9)
0.87 
(0.65-1.15)
0.76 
(0.58-1.00) 10 (14.7)
0.71
 (0.38-1.33)
0.61 
(0.33-1.15)
Use of IUD
Never 260 (14.8) 1e 1e 187 (27.2) 1e 1e 70 (19.7) 1e 1e
Only past use 8 (8.6)
0.58 
(0.30-1.14)
1.00 
(0.50-1.98)
21 (32.8)
1.21
 (0.83-1.75)
1.30
 (0.90-1.86)
2 (10.0)
0.51 
(0.13-1.93)
0.65
 (0.17-2.45)
Current use 4 (10.3)
0.69
 (0.27-1.77)
1.01 
(0.41-2.52)
1 (33.3)
1.23 
(0.25-6.10)
NA 5 (29.4)
1.50 
(0.70-3.22)
1.78 
(0.83-3.79)
Use of Estro-progestinic drugs (EP)
Never 76 (13.3) 1e 1e 109 (27.8) 1e 1e 51 (20.0) 1e 1e
Only past use 108 (12.7)
0.96 
(0.73-1.26)
0.92
 (0.71-1.20)
92 (27.0)
0.97 
(0.77-1.23)
0.97
 (0.77-1.23)
17 (17.2)
0.86
(0.52-1.41)
0.81 
(0.50-1.33)
Only current use 33 (16.8)
1.26 
(0.87-1.84)
0.99
 (0.68-1.42)
1 (50.0)
1.80 
(0.45-7.26)
NA 5 (25.0)
1.25
 (0.56-2.78)
1.00 
(0.45-2.21)
Past and current 
use
55 (20.2)
1.52 
(1.11-2.09)
1.18
 (0.87-1.61)
7 (38.9)
1.40
 (0.77-2.55)
1.36
(0.76-2.42)
4 (21.1)
1.05
(0.43-2.60)
1.13 
(0.50-2.71)
 Years of use ≤5 31 (23.0)
1.73
 (1.19-2.51)
1.20
 (0.83-1.74)
4 (40.0)
1.44 
(0.66-3.12)
1.58 
(0.73-3.40)
1 (7.1)
0.36 
(0.05-2.40)
NA
>5 20 (16.1)
1.22 
(0.77-1.91)
1.06
 (0.69-1.64)
3 (37.5)
1.35
 (0.54-3.35)
1.05 
(0.44-2.52)
2 (50.0)
2.50
 (0.91-6.87)
2.63 
(0.93-7.46)
 χ2trend 
(p-value) 2.67 (0.102) 0.29 (0.589) 0.98 (0.323) 0.27 (0.603) 0.11 (0.743) -
Number of deliveries
0 218 (19.1) 1e 1e 105 (30.6) 1e 1e 38 (23.0) 1e 1e
1 32 (10.2)
0.53 
(0.38-0.76)
0.69
 (0.48-1.01)
69 (27.8)
0.91 
(0.70-1.17)
0.92 
(0.72-1.19)
24 (19.0)
0.83
 (0.52-1.30)
0.91 
(0.58-1.43)
≥2 23 (5.1)
0.27 
(0.18-0.41)
0.45
 (0.28-0.72) 41 (23.6)
0.77 
(0.56-1.05)
0.78
 (0.57-1.08)
22 (17.5)
0.76 
(0.47-1.21)
1.02 
(0.59-1.76)
χ2trend 
(p-value)
47.37 
(<0.001)
12.44 
(<0.001) 2.75 (0.097) 2.23 (0.136) 1.43 (0.232) 0.00 (0.963)
Number of pregnancies
0 200 (19.3) 1e 1e 55 (30.9) 1e 1e 25 (19.7) 1e 1e
1 36 (12.1)
0.63
 (0.45-0.87)
0.76 
(0.54-1.06)
68 (30.1)
0.91
 (0.70-1.17)
1.01 
(0.76-1.34)
27 (25.0)
1.27 
(0.79-2.05)
1.36 
(0.85-2.19)
2 25 (7.2)
0.37
 (0.25-0.55)
0.58 
(0.37-0.90) 44 (23.2)
0.76
 (0.53-1.09)
0.77
 (0.57-1.07)
18 (20.9)
1.06 
(0.62-1.83)
1.27
 (0.73-2.23)
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SPW (N=1910) HIW (N=766) RMW (N=417)
HPV 
infection 
N=273
N (P)
Crude
PRa
(95% CI)
Adjusted
PRb
(95% CI)
HPV infection 
N=215
N (P)
Crude
PRa
(95% CI)
Adjusted
PRc
(95% CI)
HPV 
infection 
N=84
N (P)
Crude
PRa (95% CI) AdjustedPRd (95% CI)
≥3 12 (5.3)
0.27 
(0.16-0.48)
0.44
 (0.24-0.80) 48 (28.2)
0.79 
(0.48-1.30)
0.90 
(0.66-1.25)
14 (14.6)
0.74 
(0.41-1.35)
0.99 
(0.52-1.88)
χ2trend 
(p-value)
43.93 
(<0.001)
11.06 
(0.001) 1.12 (0.290) 1.35 (0.248) 0.98 (0.322) 0.03 (0.859)
SPW (N=1910) HIW (N=766) RMW (N=417)
HPV 
infection 
N=273
N (P)
Crude
PRa
(95% CI)
Adjusted
PRb
(95% CI)
HPV 
infection 
N=215
N (P)
Crude
PRa
(95% CI)
Adjusted
PRc
(95% CI)
HPV 
infection 
N=84
N (P)
Crude
PRa
(95% CI)
Adjusted
PRd
(95% CI)
Spontaneous abortion
No 255 (15.0) 1e 1e 180 (28.0) 1e 1e 74 (20.3) 1e 1e
Yes 18 (8.5)
0.56
(0.36-0.89)
0.80
(0.50-1.28)
35 (28.7)
1.02
(0.75-1.39)
1.05
(0.78-1.41)
10 (19.2)
0.95
(0.52-1.72)
1.01
(0.56-1.81)
Menopause
No 260 (14.8) 1e 1e 173 (28.6) 1e 1e 80 (20.0) 1e 1e
Yes 9 (6.4)
0.43
(0.23-0.82)
0.95
(0.48-1.88)
34 (23.6)
0.82
(0.60-1.13)
1.11
(0.79-1.56)
4 (25.0)
1.25
(0.52-2.99)
1.73
(0.69-4.31)
Self reported History of past STIs and/or genital infections
No 166 (13.0) 1e 1e 78 (21.1) 1e 1e 65 (19.8) 1e 1e
Yes 106 (17.0)
1.32
(1.05-1.65)
1.23
(0.99-1.53) 134 (34.5)
1.64
(1.29-2.08)
1.42
(1.10-1.84) 19 (22.4)
1.13
(0.72-1.77)
1.06
(0.68-1.65)
Self reported History of past STIs and/or genital infections by types
Genital warts 26 (30.2)
2.23
(1.59-3.14)
1.80
(1.31-2.49) 59 (42.5)
1.72
(1.35-2.18)
1.49
(1.17-1.89) 3 (60.0)
3.02 
(1.44-
6.35)
3.26 
(1.55-6.88)
Mycosis 70 (14.4)
1.01
(0.79-1.30)
0.98
(0.77-1.25)
65 (34.8)
1.35
(1.06-1.72)
1.12
(0.85-1.48)
10 (21.3)
1.05
(0.59-1.89)
1.06 
(0.60-1.88)
Bacterial vaginosis 14 (22.2)
1.58
(0.99-2.55)
1.35
(0.86-2.13)
23 (24.0)
0.84
(0.58-1.22)
0.68
(0.47-1.01)
3 (12.5)
0.60 
(0.20-1.76)
0.53 
(0.18-1.55)
HSV 14 (35.9)
2.59
(1.68-4.00)
2.33
(1.58-3.43) 22 (41.5)
1.54
(1.09-2.17)
1.39
(1.01-1.91) 0 (0.0) - -
Trichomoniasis 3 (13.0)
0.91
(0.32-2.63)
0.81
(0.29-2.28)
11 (39.3)
1.43
(0.89-2.29)
1.61
(1.00-2.61) - - -
Chlamydia 4 (15.4)
1.08
(0.43-2.67)
1.01
(0.42-2.44)
5 (29.4)
1.05
(0.50-2.22)
1.09
(0.52-2.26)
0 (0.0) - -
Syphilis 0 (0.0) - - 9 (39.1)
1.42
(0.84-2.39)
1.26
(0.79-2.03)
0 (0.0) - -
Gonorrhea - - - 1 (16.7)
0.59 (0.10-
3.57)
NA  0 (0.0) - -
 LGV  0 (0.0) - - 0 (0.0) - -  0 (0.0) - -
At least one STI, 
other than warts
80 (14.9)
1.15 (0.90-
1.47)
1.09 (0.86-
1.38)
75 (30.1)
1.43 (1.09-
1.88)
1.26 (0.94-
1.70)
16 (20.0)
1.01 (0.62-
1.65)
0.95 (0.59-
1.55)
SPW (N=1910) HIW (N=766) RMW (N=417)
HPV 
infection 
N=273
N (P)
Crude
PRa
(95% CI)
Adjusted
PRb
(95% CI)
HPV 
infection 
N=215
N (P)
Crude
PRa
(95% CI)
Adjusted
PRc
(95% CI)
HPV 
infection 
N=84
N (P)
Crude
PRa
(95% CI)
Adjusted
PRd
(95% CI)
Previous PAP screening timing
Regular timing 
(every 2-3 years)
180 (13.9) 1e 1e 152 (26.7) 1e 1e 27 (23.7) 1e 1e
Irregular timing 38 (12.7)
0.92
 (0.66-1.27)
1.02
 (0.75-1.40)
46 (29.1)
1.09
 (0.82-1.44)
1.02
 (0.78-1.34)
15 (17.2)
0.73
 (0.41-1.28)
0.78 
(0.45-1.38)
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SPW (N=1910) HIW (N=766) RMW (N=417)
HPV 
infection 
N=273
N (P)
Crude
PRa
(95% CI)
Adjusted
PRb
(95% CI)
HPV 
infection 
N=215
N (P)
Crude
PRa
(95% CI)
Adjusted
PRc
(95% CI)
HPV 
infection 
N=84
N (P)
Crude
PRa
(95% CI)
Adjusted
PRd
(95% CI)
Never done 55 (17.8)
1.28
 (0.97-1.69)
1.03 
(0.77-1.37)
14 (42.4)
1.59
(1.04-2.42)
1.19 
(0.77-1.83)
42 (19.4)
0.82
 (0.54-1.26)
0.90 
(0.55-1.47)
Previous PAP screening and result
Never done 55 (17.8)
1.42 
(1.08-1.87)
1.12 
(0.83-1.50)
14 (42.4)
1.81
 (1.19-2.76)
1.42 
(0.90-2.23)
42 (19.4)
0.92 
(0.63-1.36)
0.99 
(0.63-1.54)
Negative 190 (12.5) 1e 1e 144 (23.5) 1e 1e 41 (21.0) 1e 1e
Positive 23 (40.4)
3.22
 (2.29-4.54)
2.00 
(1.46-2.74) 46 (54.1)
2.31 
(1.81-2.94)
1.88
 (1.46-2.43) 1 (25.0)
1.19
(0.21-6.63)
NA
Unknown 5 (20.8) - - 8 (26.7) - - 0 (0.0) - -
VALHIDATE cyto/histological test result
Negative 197 (11.1) 1e 1e 136 (21.2) 1e 1e 64 (16.8) 1e 1e
Positive 76 (59.4)
5.41
 (4.46-6.57)
4.09 
(3.38-4.95) 79 (63.2)
2.98
 (2.44-3.64)
2.53 
(2.01-3.18) 20 (57.1)
3.41 
(2.37-4.91)
3.01 
(2.07-4.38)
NA, Not Appropriate: prevalence ratio estimate from multivariate log-binomial regression model was not reported because only one patient was 
positive to the HPV test in this factor’s level.aPrevalence ratio estimates from univariate log-binomial regression models.
bPrevalence ratio estimates from multivariate log-binomial regression models adjusted for study center, age, level of education, smoking habit and 
number of lifetime sexual partners, when appropriate. 
cPrevalence ratio estimates from multivariate log-binomial regression models adjusted for study center, age, smoking habit, number of lifetime 
sexual partners and number of CD4, when appropriate.dPrevalence ratio estimates from multivariate log-binomial regression models adjusted for age, geographical origin and number of lifetime sexual 
partners, when appropriate. eReference category.
Table 4: Number (N), prevalence (P), and prevalence ratios (PR) of cyto/histological abnormality (any lesion) and corresponding 95% confidence 
intervals (CIs), according to selected socio-demographics characteristics, smoking and sexual habits, reproductive and gynecological history, in the 
control group (SPW), the HIV group (HIW), and the recent migrant group (RMW). The number (N) and prevalence (P) of high grade intraepithelial 
lesions (HG-SIL) were also showed.
SPW (N=1910) HIW (N=766) RMW (N=417)
Any lesion
N=128
HG-SIL
N=13
Any lesion
N=125
HG-SIL
N=17
Any lesion
N=35
HG-SIL
N=6
N (P)
PRa
(95% CI)
N (P) N (P)
PRa
 (95% CI)
N (P) N (P)
PRb
(95% CI)
N (P)
Age (years)
18-25 53 (10.4) 1c 3 (0.6) 8 (24.2) 1c 0 (0.0) 16 (10.5) 1c 1 (0.7)
26-35 32 (6.1)
0.53 
(0.34-0.82) 5 (1.0) 29 (24.2)
0.96
(0.48-1.89)
3 (2.5) 9 (6.3)
0.53 
(0.24-1.17)
0 (0.0)
36-45 29 (4.7)
0.44 
(0.28-0.68) 3 (0.5) 40 (12.0)
0.47 
(0.24-0.91) 5 (1.5) 9 (7.7)
0.69 
(0.32-1.50)
5 (4.3)
>45 14 (5.4)
0.56 
(0.32-0.99) 2 (0.8) 48 (17.1)
 0.67
(0.35-1.29)
9 (3.2) 1 (25.0) NA 0 (0.0)
χ2trend (p-value) 10.42 (0.001) 2.70 (0.100) 1.18 (0.277)
Geographical origin
Italy 121 (6.8)
1.36 
(0.65-2.84)
13 (0.7) 97 (15.7)
0.79 
(0.53-1.19)
12 (1.9) - - -
Africa 0 (0.0) - 0 (0.0) 17 (20.5)
1.30
(0.81-2.11)
3 (3.6) 3 (6.8)
0.86 
(0.28-2.69)
1 (2.3)
Asia 0 (0.0) - 0 (0.0) 2 (22.2)
1.39
(0.40-4.80)
1 (11.1) 2 (10.0)
2.01 
(0.49-8.14)
0 (0.0)
Europe 4 (6.1)
0.86
(0.33-2.25)
0 (0.0) 3 (12.0)
0.72
(0.25-2.12)
0 (0.0) 11 (9.5)
1.14 
(0.58-2.26)
2 (1.7)
Latin America 3 (5.5)
0.89
 (0.29-2.68)
0 (0.0) 6 (20.7)
1.34
(0.64-2.81)
1 (3.4) 19 (8.0)
0.84 
(0.45-1.59)
3 (1.3)
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Table 4: Number (N), prevalence (P), and prevalence ratios (PR) of cyto/histological abnormality (any lesion) and corresponding 95% confidence 
intervals (CIs), according to selected socio-demographics characteristics, smoking and sexual habits, reproductive and gynecological history, in the 
control group (SPW), the HIV group (HIW), and the recent migrant group (RMW). The number (N) and prevalence (P) of high grade intraepithelial 
lesions (HG-SIL) were also showed.
SPW (N=1910) HIW (N=766) RMW (N=417)
Any lesion
N=128
HG-SIL
N=13
Any lesion
N=125
HG-SIL
N=17
Any lesion
N=35
HG-SIL
N=6
N (P)
PRa
(95% CI)
N (P) N (P)
PRa
 (95% CI)
N (P) N (P)
PRb
(95% CI)
N (P)
Marital status
Unmarried 80 (8.1) 1c 7 (0.7) 46 (22.0) 1c 7 (3.3) 20 (11.1) 1c 0 (0.0)
Married 26 (3.8)
0.67
(0.40-1.11)
4 (0.6) 34 (12.8)
0.60 
(0.40-0.91) 4 (1.5) 8 (5.0)
0.53 
(0.23-1.18)
3 (1.9)
Cohabitant 7 (6.8)
0.89
(0.42-1.89)
1 (1.0) 16 (14.2)
0.65
 (0.38-1.09)
1 (0.9) 3 (8.6)
0.85 
(0.27-2.69)
1 (2.9)
Other (divorced or widow) 15 (10.9)
1.86 
(0.98-3.53)
1 (0.7) 29 (16.3)
0.73 
(0.46-1.14)
5 (2.8) 4 (9.3)
0.79 
(0.28-2.28)
2 (4.7)
Education
Primary school 12 (4.5) 1c 0 (0.0) 64 (17.1) 1c 5 (1.3) 16 (10.8) 1c 3 (2.0)
Secondary school 81 (7.7)
1.45
 (0.80-2.62)
8 (0.8) 54 (16.3)
0.92 
(0.65-1.28)
12 (3.6) 14 (6.8)
0.60 
(0.30-1.18)
2 (1.0)
University degree 35 (5.9)
1.07
(0.56-2.03)
5 (0.8) 6 (10.3)
0.59
(0.27-1.31)
0 (0.0) 5 (7.8)
0.67 
(0.26-1.74)
1 (1.6)
χ2trend (p-value) 0.25 (0.615) 1.42 (0.233) 1.43 (0.232)
SPW (N=1910) HIW (N=766) RMW (N=417)
Any lesion
N=128
HG-SIL
N=13
Any lesion
N=125
HG-SIL
N=17
Any lesion
N=35
HG-SIL
N=6
N (P)
PRa
(95% CI)
N (P) N (P)
PRa
(95% CI)
N (P) N (P)
PRb
(95% CI)
N (P)
Smoking habit
Never/ex smoker 81 (5.9) 1c 7 (0.5) 55 (13.3) 1c 6 (1.5) 29 (8.1) 1c 5 (1.4)
Current smoker 47 (8.9)
1.34 
(0.95-1.90)
6 (1.1) 70 (19.9)
1.54 
(1.09-2.17) 11 (3.1) 6 (10.3)
1.04 
(0.45-2.41)
1 (1.7)
 1-10 cig./day 30 (8.0)
1.16
(0.77-1.74)
4 (1.1) 27 (19.3)
1.51 
(0.98-2.31)
6 (4.3) 4 (10.0)
1.00
(0.37-2.73)
0 (0.0)
>10 cig./day 17 (11.0)
1.81 
(1.10-2.96) 2 (1.3) 43 (20.3)
1.56 
(1.06-2.29) 5 (2.4) 2 (11.1)
1.11
(0.29-4.30)
1 (5.6)
χ2trend (p-value) 4.66 (0.031) 5.37 (0.020) 0.02 (0.901)
Age at first sexual intercourse
≤16 38 (8.0) 1c 4 (0.8) 50 (16.8) 1c 8 (2.7)  14 (12.6) 1c 2 (1.8)
17-18 49 (6.9)
1.00
(0.66-1.51)
4 (0.6) 44 (15.9)
0.98
(0.67-1.42)
7 (2.5) 13(9.2)
0.75
(0.37-1.53)
3 (2.1)
≥19 40 (5.6)
0.98
(0.62-1.54)
5 (0.7) 28 (15.5)
0.96
(0.61-1.50)
1 (0.6)  8 (4.9)
0.46
(0.20-1.07)
1 (0.6)
χ2trend (p-value) 0.01 (0.927) 0.04 (0.841) 3.30 (0.069)
Number or lifetime sexual
 partners
1 19 (4.1) 1c 1 (0.2) 11 (15.9) 1c 2 (2.9) 6 (4.3) 1c 2 (1.4)
2-5 70 (6.8)
1.62 
(0.99-2.66)
8 (0.8) 57 (14.7)
0.93 
(0.52-1.69)
7 (1.8) 28 (11.3)
2.71 
(1.15-6.41) 4 (1.6)
>5 39 (9.4)
2.28 
(1.34-3.88) 4 (1.0) 55 (18.2)
1.19 
(0.65-2.16)
7 (2.3) 1 (3.6) NA 0 (0.0)
χ2trend (p-value) 9.71 (0.002) 1.19 (0.275) -
Number of sexual partners in the last 6 months
0 7 (5.1) 1c 1 (0.7) 37 (18.7) 1c 7 (3.5) 11 (7.3) 1c 3 (2.0)
1 102 (6.2)
1.15 
(0.55-2.43)
10 (0.6) 84 (15.5)
0.81 
(0.57-1.17)
10 (1.8) 23 (9.3)
1.12
(0.56-2.24)
3 (1.2)
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SPW (N=1910) HIW (N=766) RMW (N=417)
Any lesion
N=128
HG-SIL
N=13
Any lesion
N=125
HG-SIL
N=17
Any lesion
N=35
HG-SIL
N=6
N (P)
PRa
(95% CI)
N (P) N (P)
PRa
(95% CI)
N (P) N (P)
PRb
(95% CI)
N (P)
≥2 18 (15.1)
1.96 
(0.83-4.63)
1 (0.8) 3 (18.8)
0.89
(0.30-2.61)
0 (0.0) 0 (0.0) - 0 (0.0)
χ2trend (p-value) 3.60 (0.058) 0.99 (0.320) -
SPW (N=1910) HIW (N=766) RMW (N=417)
Any lesion
N=128
HG-SIL
N=13
Any lesion
N=125
HG-SIL
N=17
Any lesion
N=35
HG-SIL
N=6
N (P)
PRa
(95% CI)
N (P) N (P)
PRa
(95% CI)
N (P) N (P)
PRb
(95% CI)
N (P)
Use of any type of  contraceptive methods
Never 8 (4.1) 1c 2 (1.0) 17 (25.4) 1c 4 (6.0) 7 (7.7) 1c 0 (0.0)
Only past use 38 (5.1)
1.16
(0.55-2.44)
4 (0.5) 44 (15.9)
0.61 
(0.36-1.01)
5 (1.8) 13 (7.4)
0.76 
(0.31-1.86)
4 (2.3)
Current use 82 (8.5)
1.67
(0.81-3.46)
7 (0.7) 63 (15.1)
0.54 
(0.33-0.88) 7 (1.7) 15 (10.0)
0.96
(0.40-2.31)
2 (1.3)
Use of condom
Never 49 (6.4) 1c 7 (0.9) 32 (21.9) 1c 6 (4.1) 20 (8.3) 1c 4 (1.7)
Only past use 41 (6.2)
0.83
(0.55-1.25)
4 (0.6) 30 (14.4)
0.63 
(0.40-0.99) 4 (1.9) 5 (6.0)
0.62 
(0.24-1.61)
1 (1.2)
Current use 37 (7.9)
0.98 
(0.64-1.50)
2 (0.4) 61 (15.2)
0.62 
(0.41-0.93) 6 (1.5) 9 (13.2)
1.30 
(0.61-2.75)
0 (0.0)
Use of IUD
Never 123 (7.0) 1c 13 (0.7) 113 (16.4) 1c 14 (2.0) 30 (8.4) 1c 4 (1.1)
Only past use 4 (4.3)
0.83
(0.31-2.24)
0 (0.0) 10 (15.6)
1.01 
(0.56-1.85)
2 (3.1) 2 (10.0)
1.40 
(0.36-5.38)
1 (5.0)
Current use 0 (0.0) - 0 (0.0) 1 (33.3) NA 0 (0.0) 2 (11.8)
1.55 
(0.41-5.84)
0 (0.0)
Use of Estro-progestinic drugs (EP)
Never 33 (5.8) 1c 4 (0.7) 70 (17.9) 1b 11 (2.8) 22 (8.6) 1b 4 (1.6)
Only past use 47 (5.5)
0.94
(0.61-1.44)
4 (0.5) 48 (14.1)
0.79 
(0.56-1.11)
4 (1.2) 9 (9.1)
0.96
(0.46-2.01)
1 (1.0)
Only current use  20 (10.2)
1.51 
(0.88-2.59)
3 (1.5) 2 (100.0) - 0 (0.0) 1 (5.0) NA 0 (0.0)
Past and current use 27 (9.9)
1.52
(0.93-2.48)
2 (0.7) 3 (16.7)
0.98 
(0.34-2.80)
1 (5.6)  2 (10.5)
1.25 
(0.32-4.84)
0 (0.0)
 Years of use≤5 19 (14.1)
1.73 
(0.99-3.03)
2 (1.5) 2 (20.0)
1.31
(0.38-4.51)
0 (0.0) 1 (7.1) NA 0 (0.0)
>5 8 (6.5)
1.00
(0.48-2.11)
0 (0.0) 1 (12.5)
0.67
(0.11-4.19)
1 (12.5) 0 (0.0) - 0 (0.0)
χ2trend (p-value) 0.39 (0.535) 0.05 (0.832)
SPW (N=1910) HIW (N=766) RMW (N=417)
Any lesion
N=128
HG-SIL
N=13
Any lesion
N=125
HG-SIL
N=17
Any lesion
N=35
HG-SIL
N=6
N (P)
PRa
(95% CI)
N (P) N (P)
PRa
(95% CI)
N (P) N (P)
PRb
(95% CI)
N (P)
Number of deliveries
0 90 (7.9) 1c 10 (0.9) 54 (15.7) 1c 6 (1.7) 17 (10.3) 1c 1 (0.6)
1 15 (4.8)
0.81 
(0.46-1.45)
2 (0.6) 48 (19.4)
1.23
(0.86-1.75)
8 (3.2) 5 (4.0)
0.41 
(0.15-1.08)
0 (0.0)
≥2 23 (5.1)
1.07
(0.61-1.88)
1 (0.2) 23 (13.2)
0.85
(0.53-1.36)
3 (1.7) 13 (10.3)
1.22 
(0.54-2.73)
5 (4.0)
χ2trend (p-value) 0.01 (0.934) 0.09 (0.766) 0.03 (0.868)
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SPW (N=1910) HIW (N=766) RMW (N=417)
Any lesion
N=128
HG-SIL
N=13
Any lesion
N=125
HG-SIL
N=17
Any lesion
N=35
HG-SIL
N=6
N (P)
PRa
(95% CI)
N (P) N (P)
PRa
(95% CI)
N (P) N (P)
PRb
(95% CI)
N (P)
Number of pregnancies
0 80 (7.7) 1c 8 (0.8) 28 (15.7) 1c 4 (2.2) 12 (9.4) 1c 0 (0.0)
1 19 (6.4)
1.08
(0.65-1.80)
3 (1.0) 40 (17.7)
1.10
(0.71-1.72)
7 (3.1) 7 (6.5)
0.71 
(0.29-1.73)
1 (0.9)
2 21 (6.0)
1.23
(0.71-2.15)
2 (0.6) 30 (15.8)
1.01
(0.63-1.62)
2 (1.1) 7 (8.1)
0.89 
(0.35-2.26)
1 (1.2)
≥3 8 (3.5)
0.77
(0.35-1.70)
0 (0.0) 27 (15.9)
1.00 
(0.61-1.63)
4 (2.4) 9 (9.4)
1.11 
(0.45-2.73)
4 (4.2)
χ2trend (p-value) 0.01 (0.922) 0.02 (0.886) 0.05 (0.825)
Spontaneous abortion
No 119 (7.0) 1c 13 (0.8) 107 (16.6) 1c 15 (2.3) 30 (8.2) 1c 5 (1.4)
Yes 9 (4.2)
0.76 
(0.38-1.50)
0 (0.0) 18 (14.8)
0.89 
(0.56-1.41)
2 (1.6) 5 (9.6)
1.09 
(0.44-2.71)
1 (1.9)
Menopause
No 119 (6.8) 1c 11 (0.6) 101 (16.7) 1c 12 (2.0) 34 (8.5) 1c 5 (1.2)
Yes 6 (4.3)
0.89
(0.39-2.06)
2 (1.4) 19 (13.2)
0.85
(0.52-1.41)
4 (2.8) 1 (6.3) NA 1 (6.3)
SPW (N=1910) HIW (N=766) RMW (N=417)
Any lesion
N=128
HG-SIL
N=13
Any lesion
N=125
HG-SIL
N=17
Any lesion
N=35
HG-SIL
N=6
N (P)
PRa
(95% CI)
N (P) N (P)
PRa
(95% CI)
N (P) N (P)
PRb
(95% CI)
N (P)
Self reported history of past STIs and/or genital infections
No 80 (6.2) 1c 7 (0.6) 51 (13.8) 1c 3 (0.8) 24 (7.3) 1c 6 (1.8)
Yes 47 (7.6)
1.21
(0.86-1.72)
6 (1.0) 71 (18.3)
1.27
(0.87-1.84)
13 (3.4) 10 (11.8)
1.47 
(0.73-2.96)
0 (0.0)
Self reported history of past STIs and/or genital infections by types
Genital warts 15 (17.4)
2.67
 (1.63-4.36) 3 (3.5) 35 (25.2)
1.75 
(1.22-2.51) 6 (4.3) 2 (40.0)
4.68 
(1.58-13.90) 0 (0.0)
Mycosis 27 (5.6)
0.80
(0.53-1.20)
3 (0.6) 33 (17.7)
0.99 
(0.64-1.52)
5 (2.7) 5 (10.6)
1.34 
(0.55-3.28)
0 (0.0)
Bacterial vaginosis 7 (11.1)
1.58
(0.77-3.24)
0 (0.0) 14 (14.6)
0.79
(0.45-1.39)
2 (2.1) 3 (12.5)
1.30 
(0.43-3.98)
0 (0.0)
HSV 5 (12.8)
1.99
(0.86-4.59)
0 (0.0) 14 (26.4)
1.63 (1.00-
2.66) 2 (3.8) 0 (0.0) - 0 (0.0)
Trichomoniasis 2 (8.7)
1.30
(0.34-4.93)
0 (0.0) 5 (17.9)
0.86
(0.23-3.26)
2 (7.1) 0 (0.0) - 0 (0.0)
Chlamydia 2 (7.7)
1.16
(0.30-4.40)
0 (0.0) 2 (11.8)
0.73 
(0.19-2.71)
0 (0.0) 0 (0.0) - 0 (0.0)
Syphilis 0 (0.0) - 0 (0.0) 5 (21.7)
1.35
(0.61-3.01)
0 (0.0) 0 (0.0) - 0 (0.0)
Gonorrhea - - - 2 (33.3)
2.17
(0.69-6.78)
1 (16.7) 0 (0.0) - 0 (0.0)
 LGV 0 (0.0) - 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 0 (0.0)
At least one STI, other than 
warts
32 (6.0)
0.96 
(0.65-1.44)
3 (0.6) 36 (14.5)
1.10
(0.70-1.75)
7 (2.8) 8 (10.0)
1.26
(0.59-2.71)
0 (0.0)
Previous PAP screening timing
Regular timing (every 2-3 
years)
85 (6.6) 1c 11 (0.8) 89 (15.6) 1c 10 (1.8) 8 (7.0) 1c 2 (1.8)
Irregular timing 10 (3.3)
0.54
(0.28-1.02)
1 (0.3) 26 (16.5)
1.10 
(0.73-1.64)
4 (2.5) 5 (5.7)
0.86 
(0.29-2.53)
0 (0.0)
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SPW (N=1910) HIW (N=766) RMW (N=417)
Any lesion
N=128
HG-SIL
N=13
Any lesion
N=125
HG-SIL
N=17
Any lesion
N=35
HG-SIL
N=6
N (P)
PRa
(95% CI)
N (P) N (P)
PRa
(95% CI)
N (P) N (P)
PRb
(95% CI)
N (P)
Never done 33 (10.7)
1.44
(0.93-2.21)
1 (0.3) 8 (24.2)
1.44
(0.72-2.86)
2 (6.1) 22 (10.2)
1.76 
(0.80-3.88)
4 (1.9)
Previous PAP screening and result
Never done 33 (10.7)
1.96 
(1.26-3.06) 1 (0.3) 8 (24.2)
1.85
(0.92-3.72)
2 (6.1) 22 (10.2)
1.95 
(0.98-3.91)
4 (1.9)
Negative 75 (4.9) 1c 11 (0.7) 73 (11.9) 1c 5 (0.8) 12 (6.2) 1c 2 (1.0)
Positive 19 (33.3)
5.88 
(3.79-9.14) 1 (1.8) 38 (44.7)
3.81 
(2.74-5.31) 8 (9.4) 1 (25.0) NA 0 (0.0)
Unknown 1 (4.2) - 0 (0.0) 4 (13.3) - 1 (3.3) 0 (0.0) - 0 (0.0)
NA, Not Appropriate: prevalence ratio estimate from multivariate log-binomial regression model was not reported because only one patient was 
positive to the cyto/histological test in this factor’s level.aPrevalence ratio estimates from multivariate log-binomial regression models adjusted for study center, age, and number of lifetime sexual partners.
bPrevalence ratio estimates from multivariate log-binomial regression models adjusted for age and number of lifetime sexual partners.
cReference category.
types fell from 27.3% in 20–29-y.o. women to 10.3% in those 
aged 30–39 years. In our study we confirmed that HPV infection 
is strongly linked to age with the highest burden in younger ages, 
both in the general population and in the testing groups although 
at different prevalence levels: prevalence fall from 27.5% to 
12.8% in RMW, from 51.5% to 24% in HIW, and from 21.3% 
to 8.4% in SPW in the 18–26 y.o. and 36–45 y.o. subgroups, 
respectively. The prospective longitudinal study to evaluate 
sensitivity and positive predictive value of HPV testing in these 
high-risk populations is ongoing.
The small sample size and young age of the RMW group 
could have affected the ability to identify statistical associations 
between risk factors and HPV infection or cervical lesions. 
We chose to enroll only migrant women in their first year of 
migration, a population with a large proportion of young and 
healthy women who rarely seek medical attention except for 
pregnancy and emergencies. The HPV prevalence estimated 
from the RMW group (20.1%; 95% CI: 16.2–24.0), reflects both 
their young age and geographical origins (i.e. Latin America and 
Eastern Europe) [32-34]. The VALHIDATE study, which recruited 
migrant women from a Catholic outpatient primary health 
care ward for uninsured migrating people, may thus provide 
interesting data on health, sexual and reproductive habits of this 
population with limited access to public health facilities and for 
whom such data are limited, even if they only partially represent 
the migrant population in Lombardy [35]. 
The greater susceptibility to infection in high-risk women 
enrolled in this study has been attributed to several factors 
ranging from immunological, behavioral or social causes [36]. 
Lack of access to screening programs is suggested to be the major 
cause of an excess burden of cervical pre-cancer and cancers in 
migrant women [5]. In HIV-infected people, increased risk of 
reactivation of latent infections and reduced viral clearance by 
the impaired immune system, as well as greater exposure to 
STIs has been proposed to explain the higher prevalence of HPV 
infection in all age classes, its longer persistence and the higher 
risk of invasive diseases [37].
Our data are not addressed to verify the role of immune 
mechanisms underlying the greatest susceptibility of HIV-
infected women to HPV diseases but we investigated the 
behavioral or social causes associated with higher risk of infection 
that can be modified through specifically addressed public health 
intervention and cervical cancer screening. We found that in the 
HIW group, cigarette smoking and history of past STIs (namely, 
history of genital warts, genital HSV infection and trichomoniasis) 
are independently associated with increased risk of HPV 
infection, whereas being married and using contraceptives—
particularly condoms—are associated with decreased risk of 
HPV infection. The smaller association in the HIW group between 
number of lifetime sexual partners and HPV infection than in the 
other groups could be explained by their high use of condoms. 
Condoms were used by most of the HIV-infected patients who 
were cared for and followed up in outpatient wards for HIV+ 
persons as part of safe-sex procedures recommended to prevent 
transmission of HIV and other STIs [38]. The effectiveness of 
condom use in preventing HPV transmission is not proven but 
several studies show a trend of protective effect [39,40] along 
with protection against other STIs. In the other two groups, SPW 
and RMW, who prefer estroprogestinic drugs as contraceptive 
method, the number of lifetime and recent sexual partners play 
an important role in risk for HPV infection, as already reported 
in literature [41]. The risk of HPV-related cervical abnormalities 
is affected differently by some factors that could be addressed 
through public health intervention. Cigarette smoking and STIs 
are associated with increased risk, and condom use with reduced 
risk, of SIL in HIV-infected women. High number of sexual 
partners and STIs are related to increased risk of SIL in SPW and 
RMW. 
Adherence to Pap screening programs has been reported to 
influence the prevalence of SIL [42]. More than 50% of migrant 
women declared that they never had a Pap smear previously, in 
compared with 16% of the controls and 4% of the HIV-infected 
women. Risk of SIL was found to be greater in women who had 
never had Pap screening than for those with a previous positive 
Pap test, even when adjusted by age. A low adherence to Pap 
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screening programs was strongly associated with increased HPV 
risk in both RMW and SPW. This parameter was not confirmed 
for risk of SIL in HIW, although a higher prevalence of SIL was 
found in HIW who had never had a previous Pap test, compared 
with those with regular or even irregular Pap screening (24.2% 
vs 15.6 and 16.5% respectively). Some questions on best 
practices for HPV screening in the general population and in high 
risk women (age to begin HPV screening, interval between the 
two HPV screening rounds, time and screening method after HPV 
vaccination) [26-28,43-45] remain unanswered. 
CONCLUSIONS
Several conclusions can be inferred from our data. HPV-based 
screening provides greater prevention than Pap screening when 
performed in women over 30 years of age, allowing an earlier 
detection of invasive diseases at the first screening round; this 
gain could be larger in settings where the quality of cytology is 
lower; moreover HPV-based screening allows a safe extension 
of screening intervals to 5 years [28,42]. In this work we found 
some important differences in risk factors that influence HPV 
infection in selected populations, and provide some data to 
guide specific public health interventions for cancer prevention. 
Development of the optimal screening strategy depends on 
several considerations besides the most appropriate screening 
test. Knowledge of modifiable epidemiological factors that affect 
HPV infections in women could help identify a global strategy of 
intervention that includes health education and sexual health 
education, promotion of safe sex procedures, and allocation of 
resources for measures to promote adhesion to screening and 
preventing programs in more vulnerable people. 
In conclusion, our results showed that a very wide range of 
social and behavioral determinants can affect women’s sexual 
health and their risk of cervical HPV infections and diseases. 
Several factors included in our analyses could be modified 
through public health intervention and programs; interventions 
specifically aimed at decreasing social and behavioral risk 
factors could be added to HPV screening and vaccine, both for 
the general population and for those who are more vulnerable to 
HPV infection and related cancers.
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